Day One(DAWN) 董事高管_F10_同花顺金融服务网

董事介绍

注：董事持股数取自最新公司公告

姓名	性别	职位	年龄	薪酬	持股数(万股)	截止日期
Natalie Holles	女	Director	53	47.27万美元	23.35	2026-04-01
William Grossman	男	Director	56	34.04万美元	5.93	2026-04-01
John Josey	男	Director	65	44.39万美元	23.23	2026-04-01
Jeremy Bender	男	Chief Executive Officer,Director and President	54	913.44万美元	380.05	2026-04-01
Garry Nicholson	男	Chair and Director	71	42.35万美元	10.10	2026-04-01
Scott Garland	男	Director	57	46.43万美元	14.39	2026-04-01
Habib Dable	男	Director	56	34.29万美元	5.93	2026-04-01
Garry Nicholson	男	Chair and Director	71	未披露	未持股	2026-04-01
Habib Dable	--	Director	56	未披露	未持股	2026-04-01
Scott Garland	--	Director	57	未披露	未持股	2026-04-01
William Grossman	--	Director	56	未披露	未持股	2026-04-01
Saira Ramasastry	女	Director	50	48.85万美元	22.39	2026-04-01

高管介绍

注：高管持股数取自最新公司公告

姓名	性别	职位	年龄	薪酬	持股数(万股)	截止日期
Michael Vasconcelles	男	Head of Research and Development	62	373.18万美元	未持股	2026-04-01
Adam Dubow	男	Chief Compliance Officer, General Counsel and Secretary	59	404.26万美元	33.48	2026-04-01
Jeremy Bender	男	Chief Executive Officer,Director and President	54	913.44万美元	380.05	2026-04-01
Charles York II	男	Chief Financial Officer and Chief Operating Officer	49	470.76万美元	102.27	2026-04-01
Lauren Merendino	女	Chief Commercial Officer	51	261.67万美元	未持股	2026-04-01
Lauren Merendino	--	Chief Commercial Officer	51	未披露	未持股	2026-04-01
Michael Vasconcelles	--	Head of Research and Development	62	未披露	未持股	2026-04-01
Adam Dubow	男	Chief Compliance Officer, General Counsel and Secretary	59	未披露	未持股	2026-04-01

董事简历

中英对照 | 中文 | 英文

Natalie Holles: Natalie Holles，自2015年8月起担任高级副总裁兼首席运营官；2013年6月至2015年5月Hyperion Therapeutics, Inc.（罕见遗传病制药公司）被Horizon Pharma, plc收购前担任前者的企业发展高级副总裁；2012年8月至2013年6月间担任Immune Design, Inc.（免疫疗法公司）的企业发展执行副总裁；2010年12月至2013年6月间是一名独立生命科学企业发展顾问；早期担任KAI Pharmaceuticals, Inc.的业务开发副总裁，此前担任InterMune, Inc.和Genentech, Inc.的企业发展和商业化方面职位。她获得了Stanford University的学士学位，和博尔德the University of Colorado的硕士学位。

Natalie Holles has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since February 2021. From August 2021 through December 2025, she served as the Chief Executive Officer of Third Harmonic Bio, Inc. Prior to joining Third Harmonic, she served as President and Chief Executive Officer at Audentes Therapeutics, Inc., a biotechnology company focused on genetic medicines from January 2020 through March 2021, and prior to that served as their President and Chief Operating Officer beginning in May 2018, and Senior Vice President, Chief Operating Officer beginning in August 2015. Previously, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc., a rare disease pharmaceutical company, from June 2013 through its acquisition by Horizon Pharma, plc in May 2015. From August 2012 until June 2013, Ms. Holles served as the Executive Vice President, Corporate Development at Immune Design, Inc., an immunotherapy company, and from December 2010 to June 2013, Ms. Holles served as an independent life sciences corporate development consultant. Earlier in her career, Ms. Holles served as the Vice President, Business Development at KAI Pharmaceuticals, Inc., which was acquired by Amgen in 2012, and previously held corporate development and commercial roles at InterMune, Inc (acquired by Roche) and Genentech, Inc. Ms. Holles also served on the board of directors of Renasant Bio, Inc. since October 2024, and previously served on the board of directors of Rubius Therapeutics, Inc., a biopharmaceutical company, from March 2019 to August 2022 and Allakos Inc., a biotechnology company, from December 2020 to July 2021. Ms. Holles holds a B.A. in Human Biology from Stanford University and an M.A. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow. Day One Biopharmaceuticals, Inc.; Natalie Holles，自2015年8月起担任高级副总裁兼首席运营官；2013年6月至2015年5月Hyperion Therapeutics, Inc.（罕见遗传病制药公司）被Horizon Pharma, plc收购前担任前者的企业发展高级副总裁；2012年8月至2013年6月间担任Immune Design, Inc.（免疫疗法公司）的企业发展执行副总裁；2010年12月至2013年6月间是一名独立生命科学企业发展顾问；早期担任KAI Pharmaceuticals, Inc.的业务开发副总裁，此前担任InterMune, Inc.和Genentech, Inc.的企业发展和商业化方面职位。她获得了Stanford University的学士学位，和博尔德the University of Colorado的硕士学位。; Natalie Holles has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since February 2021. From August 2021 through December 2025, she served as the Chief Executive Officer of Third Harmonic Bio, Inc. Prior to joining Third Harmonic, she served as President and Chief Executive Officer at Audentes Therapeutics, Inc., a biotechnology company focused on genetic medicines from January 2020 through March 2021, and prior to that served as their President and Chief Operating Officer beginning in May 2018, and Senior Vice President, Chief Operating Officer beginning in August 2015. Previously, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc., a rare disease pharmaceutical company, from June 2013 through its acquisition by Horizon Pharma, plc in May 2015. From August 2012 until June 2013, Ms. Holles served as the Executive Vice President, Corporate Development at Immune Design, Inc., an immunotherapy company, and from December 2010 to June 2013, Ms. Holles served as an independent life sciences corporate development consultant. Earlier in her career, Ms. Holles served as the Vice President, Business Development at KAI Pharmaceuticals, Inc., which was acquired by Amgen in 2012, and previously held corporate development and commercial roles at InterMune, Inc (acquired by Roche) and Genentech, Inc. Ms. Holles also served on the board of directors of Renasant Bio, Inc. since October 2024, and previously served on the board of directors of Rubius Therapeutics, Inc., a biopharmaceutical company, from March 2019 to August 2022 and Allakos Inc., a biotechnology company, from December 2020 to July 2021. Ms. Holles holds a B.A. in Human Biology from Stanford University and an M.A. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow. Day One Biopharmaceuticals, Inc.

William Grossman: William Grossman，医学博士，博士，自2018年2月起担任首席医疗官。加入Bellicum之前，Grossman博士于2015年9月至2018年2月担任Genentech癌症免疫疗法集团医疗总监，领导胃肠道癌症癌症免疫疗法和所有实体肿瘤的癌症免疫疗法组合的全球临床开发类型。从2013年4月到2015年9月，他曾担任AbbVie公司的肿瘤学美国和全球医疗事务治疗领域主管，在那里他曾参与肿瘤疫苗、免疫调节剂和小分子/生物制剂的开发和临床研究。从2011年到2013年，Grossman博士担任BioThera的高级副总裁，研究与临床开发，在那里他监督肿瘤和免疫学的所有发现和临床开发工作。此外，从2004年到2008年，Grossman博士在威斯康星医学院和威斯康星儿童医院担任过各种职务，包括临床免疫诊断和研究实验室的创始人兼医学主任，微生物和遗传学教授，以及免疫缺陷移植计划血液学/肿瘤学/骨髓移植处处长。Grossman博士在华盛顿大学医学院（Washington University School of Medicine）获得医学博士学位和博士学位，并在华盛顿大学医学院（Washington University School of Medicine）完成了儿科-血液学/肿瘤学部门的医学培训。

William Grossman has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since January 2024. Dr. Grossman currently serves as Co Founder and Head of Research & Development of Oncko, Inc., a pharmaceutical drug development company, since November 2024. He is also the Founder of Grossman Biotech & Pharma Consulting, LLC, a consulting firm which offers fractional CMO services to biotechnology and venture capital/private equity organizations, since February 2019. Previously, he served as Senior Vice President and Oncology Therapeutic Area Head of Clinical Development at Gilead Sciences, Inc., a biopharmaceutical company, from August 2021 to August 2024. Prior to that, he held Chief Medical Officer roles at Arcus Biosciences, Inc. from April 2019 to August 2021 and Bellicum Pharmaceuticals, Inc. from February 2018 to April 2019. He has held additional leadership roles at Merck & Co., Baxter International Inc., Bio Thera Solutions Inc., AbbVie Inc. and Genentech/Roche between 2008 and 2018. He also served at the Children's Hospital of Wisconsin/Medical College of Wisconsin as Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics and Director of the Bone Marrow Transplant Division for the Immunodeficiency Transplant Program from 2004 to 2008. Dr. Grossman has served on the board of directors of enGene Holdings Inc. since July 2025. Dr. Grossman received his M.D. and Ph.D. in Immunology from Washington University School of Medicine's Medical Scientist Training Program and completed his medical and postdoctoral training in the Divisions of Pediatrics and Medicine at Washington University School of Medicine.; William Grossman，医学博士，博士，自2018年2月起担任首席医疗官。加入Bellicum之前，Grossman博士于2015年9月至2018年2月担任Genentech癌症免疫疗法集团医疗总监，领导胃肠道癌症癌症免疫疗法和所有实体肿瘤的癌症免疫疗法组合的全球临床开发类型。从2013年4月到2015年9月，他曾担任AbbVie公司的肿瘤学美国和全球医疗事务治疗领域主管，在那里他曾参与肿瘤疫苗、免疫调节剂和小分子/生物制剂的开发和临床研究。从2011年到2013年，Grossman博士担任BioThera的高级副总裁，研究与临床开发，在那里他监督肿瘤和免疫学的所有发现和临床开发工作。此外，从2004年到2008年，Grossman博士在威斯康星医学院和威斯康星儿童医院担任过各种职务，包括临床免疫诊断和研究实验室的创始人兼医学主任，微生物和遗传学教授，以及免疫缺陷移植计划血液学/肿瘤学/骨髓移植处处长。Grossman博士在华盛顿大学医学院（Washington University School of Medicine）获得医学博士学位和博士学位，并在华盛顿大学医学院（Washington University School of Medicine）完成了儿科-血液学/肿瘤学部门的医学培训。; William Grossman has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since January 2024. Dr. Grossman currently serves as Co Founder and Head of Research & Development of Oncko, Inc., a pharmaceutical drug development company, since November 2024. He is also the Founder of Grossman Biotech & Pharma Consulting, LLC, a consulting firm which offers fractional CMO services to biotechnology and venture capital/private equity organizations, since February 2019. Previously, he served as Senior Vice President and Oncology Therapeutic Area Head of Clinical Development at Gilead Sciences, Inc., a biopharmaceutical company, from August 2021 to August 2024. Prior to that, he held Chief Medical Officer roles at Arcus Biosciences, Inc. from April 2019 to August 2021 and Bellicum Pharmaceuticals, Inc. from February 2018 to April 2019. He has held additional leadership roles at Merck & Co., Baxter International Inc., Bio Thera Solutions Inc., AbbVie Inc. and Genentech/Roche between 2008 and 2018. He also served at the Children's Hospital of Wisconsin/Medical College of Wisconsin as Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics and Director of the Bone Marrow Transplant Division for the Immunodeficiency Transplant Program from 2004 to 2008. Dr. Grossman has served on the board of directors of enGene Holdings Inc. since July 2025. Dr. Grossman received his M.D. and Ph.D. in Immunology from Washington University School of Medicine's Medical Scientist Training Program and completed his medical and postdoctoral training in the Divisions of Pediatrics and Medicine at Washington University School of Medicine.

John Josey: 自2020年9月以来，John Josey一直担任我们的董事会成员。他曾于2013年8月至2019年7月担任PelotonTherapeutics，Inc.的总裁兼首席执行官，在此之前曾担任其总裁兼首席科学官。此前，Josey博士从2004年到2011年担任发现化学（Discovery Chemistry）的副总裁，从2000年到2004年担任Lead Generation的高级总监，从1998年到2000年担任Array BiopharmaInc.（一家生物技术公司）的高速合成高级总监。在加入Array之前，从1995年到1998年，Josey博士受雇于安进公司，这是一家生物制药公司，在安进公司’；s小分子药物发现计划的新线索/组合口服化学组工作。从1991年到1995年，Josey博士受雇于葛兰素研究所的药物化学部。自2018年6月以来，他一直担任德克萨斯大学西南医学中心生物化学系的兼职教师。Josey博士拥有科罗拉多州立大学的化学学士学位，科罗拉多大学的工商管理硕士学位和德克萨斯大学奥斯汀分校的有机化学博士学位。他也是加州理工学院的Damon Runyon-Walter Winchell博士后研究员。

John Josey has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since September 2020. He has been a Venture Partner with The Column Group since March 2020. He previously served as President and Chief Executive Officer, and as a member of the board of directors of Peloton Therapeutics, Inc., a biotechnology company focused on oncology drug discovery and development, from August 2013 until its acquisition by Merck in July 2019. Further, from June 1998 to August 2011, Dr. Josey served in various positions of leadership at Array Biopharma, Inc., a biotechnology company, including as the Vice President of Discovery Chemistry. Dr. Josey's previous experience within the biotechnology industry also includes serving as a scientist at Amgen, Inc. and the Glaxo Research Institute. Dr. Josey currently serves on the board of directors for private biotechnology companies, Accent Therapeutics, Inc., Atavistik Bio, Inc., Circle Pharma, Inc., Nura Bio, Inc. Reina Bio, Inc., and Tortugas Neurosciences, Inc. Dr. Josey currently serves on the board of directors of biotechnology companies Tortugas Neurosciences, Inc., since April 2025, Atavisk Bio, Inc., since January 2022 and Circle Pharma, Inc., since May 2020. Dr. Josey received a B.S. in chemistry from Colorado State University, an M.B.A. from the University of Colorado and a Ph.D. in organic chemistry from the University of Texas at Austin. He was a Damon Runyon Walter Winchell postdoctoral fellow at the California Institute of Technology. Day One Biopharmaceuticals, Inc.; 自2020年9月以来，John Josey一直担任我们的董事会成员。他曾于2013年8月至2019年7月担任PelotonTherapeutics，Inc.的总裁兼首席执行官，在此之前曾担任其总裁兼首席科学官。此前，Josey博士从2004年到2011年担任发现化学（Discovery Chemistry）的副总裁，从2000年到2004年担任Lead Generation的高级总监，从1998年到2000年担任Array BiopharmaInc.（一家生物技术公司）的高速合成高级总监。在加入Array之前，从1995年到1998年，Josey博士受雇于安进公司，这是一家生物制药公司，在安进公司’；s小分子药物发现计划的新线索/组合口服化学组工作。从1991年到1995年，Josey博士受雇于葛兰素研究所的药物化学部。自2018年6月以来，他一直担任德克萨斯大学西南医学中心生物化学系的兼职教师。Josey博士拥有科罗拉多州立大学的化学学士学位，科罗拉多大学的工商管理硕士学位和德克萨斯大学奥斯汀分校的有机化学博士学位。他也是加州理工学院的Damon Runyon-Walter Winchell博士后研究员。; John Josey has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since September 2020. He has been a Venture Partner with The Column Group since March 2020. He previously served as President and Chief Executive Officer, and as a member of the board of directors of Peloton Therapeutics, Inc., a biotechnology company focused on oncology drug discovery and development, from August 2013 until its acquisition by Merck in July 2019. Further, from June 1998 to August 2011, Dr. Josey served in various positions of leadership at Array Biopharma, Inc., a biotechnology company, including as the Vice President of Discovery Chemistry. Dr. Josey's previous experience within the biotechnology industry also includes serving as a scientist at Amgen, Inc. and the Glaxo Research Institute. Dr. Josey currently serves on the board of directors for private biotechnology companies, Accent Therapeutics, Inc., Atavistik Bio, Inc., Circle Pharma, Inc., Nura Bio, Inc. Reina Bio, Inc., and Tortugas Neurosciences, Inc. Dr. Josey currently serves on the board of directors of biotechnology companies Tortugas Neurosciences, Inc., since April 2025, Atavisk Bio, Inc., since January 2022 and Circle Pharma, Inc., since May 2020. Dr. Josey received a B.S. in chemistry from Colorado State University, an M.B.A. from the University of Colorado and a Ph.D. in organic chemistry from the University of Texas at Austin. He was a Damon Runyon Walter Winchell postdoctoral fellow at the California Institute of Technology. Day One Biopharmaceuticals, Inc.

Jeremy Bender: Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。

Jeremy Bender has served as Chief Executive Officer, President and a member of board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, Inc., a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics, Inc. from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, Inc., he was Vice President of Corporate Development at Allos Therapeutics Inc., a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma Group plc, a biotechnology company, since October 2020 as an independent board member. From October 2023 to June 2024, Dr. Bender also served as a director of Fusion Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.; Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。; Jeremy Bender has served as Chief Executive Officer, President and a member of board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, Inc., a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics, Inc. from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, Inc., he was Vice President of Corporate Development at Allos Therapeutics Inc., a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma Group plc, a biotechnology company, since October 2020 as an independent board member. From October 2023 to June 2024, Dr. Bender also served as a director of Fusion Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

Garry Nicholson: Garry Nicholson，自2024年6月起担任董事会成员。Nicholson先生拥有超过35年的制药和生物技术肿瘤学经验。2015年8月至2016年11月，他担任XTuit Pharmaceuticals的总裁兼首席执行官，同时也是该公司的董事会成员。从2008年5月开始，他在辉瑞领导全球肿瘤专营权，直到2015年5月离职，担任辉瑞肿瘤学总裁。他的职责包括全球商业化和销售、临床开发和监管战略以及业务发展。在他的领导下，这家公司开发并推出了Ibrance（palbociclib），首个在美国和欧洲获批的细胞周期蛋白依赖性激酶（“CDK”）4/6抑制剂。在辉瑞任职期间，Nicholson先生曾担任辉瑞基金会的董事会成员，并且是公司投资组合、战略和投资委员会的成员，该委员会负责制定企业研发重点和投资战略。在其职业生涯的早期，尼科尔森先生曾在礼来公司的肿瘤部门担任过多个领导职务。此外，他还曾担任AMPATH的顾问，AMPATH是一个由北美大学和健康中心、莫伊大学、莫伊教学和转诊医院以及肯尼亚政府组成的联盟，后者帮助在发展中国家建立可持续的医疗保健系统。Nicholson先生的医疗保健职业生涯始于埃默里大学的药学实习生。他目前在私营生物制药公司Abdera Therapeutics Inc.担任董事会主席，并在上市的临床和商业阶段生物制药公司Day One Biopharmaceuticals, Inc.担任董事会主席。他目前还担任私营临床阶段公司Avenzo Therapeutics的董事会成员。Nicholson先生此前曾担任商业阶段公司G1治疗、上市临床阶段生物制药公司NextCure，上市公司临床阶段精准肿瘤学公司Turning Point Therapeutics, Inc.，上市临床阶段精准肿瘤学公司Five Prime Therapeutics, Inc.的董事会成员，上市临床阶段制药公司TERM3的董事会成员TESARO，Inc.，一家上市的专注于肿瘤学的生物制药公司，一家私营生物技术公司Tmunity Therapeutics Inc.，一家私营生物技术公司SQZ Biotechnologies，Inc.，一家私营生物技术公司，以及Personal Genome Diagnostics Inc.，一家私营癌症基因组学公司。尼科尔森先生拥有南卡罗来纳大学的工商管理硕士学位，并在北卡罗来纳大学教堂山分校获得药学学士学位。

Garry Nicholson has served as chair of Day One Biopharmaceuticals, Inc.'s board of directors since September 2022. From August 2015 to October 2016 he served as President and Chief Executive Officer of XTuit Pharmaceuticals, Inc., where he was also a member of the board of directors. Mr. Nicholson joined Pfizer, Inc. in May 2008 to lead the global oncology franchise, finishing his career there as President, Pfizer Oncology in April 2015. During his tenure at Pfizer, Mr. Nicholson served on the board of directors of the Pfizer Foundation and was a member of the company's Portfolio, Strategy and Investment Committee, which set corporate research and development priorities and investment strategy. Mr. Nicholson received a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina.; Garry Nicholson，自2024年6月起担任董事会成员。Nicholson先生拥有超过35年的制药和生物技术肿瘤学经验。2015年8月至2016年11月，他担任XTuit Pharmaceuticals的总裁兼首席执行官，同时也是该公司的董事会成员。从2008年5月开始，他在辉瑞领导全球肿瘤专营权，直到2015年5月离职，担任辉瑞肿瘤学总裁。他的职责包括全球商业化和销售、临床开发和监管战略以及业务发展。在他的领导下，这家公司开发并推出了Ibrance（palbociclib），首个在美国和欧洲获批的细胞周期蛋白依赖性激酶（“CDK”）4/6抑制剂。在辉瑞任职期间，Nicholson先生曾担任辉瑞基金会的董事会成员，并且是公司投资组合、战略和投资委员会的成员，该委员会负责制定企业研发重点和投资战略。在其职业生涯的早期，尼科尔森先生曾在礼来公司的肿瘤部门担任过多个领导职务。此外，他还曾担任AMPATH的顾问，AMPATH是一个由北美大学和健康中心、莫伊大学、莫伊教学和转诊医院以及肯尼亚政府组成的联盟，后者帮助在发展中国家建立可持续的医疗保健系统。Nicholson先生的医疗保健职业生涯始于埃默里大学的药学实习生。他目前在私营生物制药公司Abdera Therapeutics Inc.担任董事会主席，并在上市的临床和商业阶段生物制药公司Day One Biopharmaceuticals, Inc.担任董事会主席。他目前还担任私营临床阶段公司Avenzo Therapeutics的董事会成员。Nicholson先生此前曾担任商业阶段公司G1治疗、上市临床阶段生物制药公司NextCure，上市公司临床阶段精准肿瘤学公司Turning Point Therapeutics, Inc.，上市临床阶段精准肿瘤学公司Five Prime Therapeutics, Inc.的董事会成员，上市临床阶段制药公司TERM3的董事会成员TESARO，Inc.，一家上市的专注于肿瘤学的生物制药公司，一家私营生物技术公司Tmunity Therapeutics Inc.，一家私营生物技术公司SQZ Biotechnologies，Inc.，一家私营生物技术公司，以及Personal Genome Diagnostics Inc.，一家私营癌症基因组学公司。尼科尔森先生拥有南卡罗来纳大学的工商管理硕士学位，并在北卡罗来纳大学教堂山分校获得药学学士学位。; Garry Nicholson has served as chair of Day One Biopharmaceuticals, Inc.'s board of directors since September 2022. From August 2015 to October 2016 he served as President and Chief Executive Officer of XTuit Pharmaceuticals, Inc., where he was also a member of the board of directors. Mr. Nicholson joined Pfizer, Inc. in May 2008 to lead the global oncology franchise, finishing his career there as President, Pfizer Oncology in April 2015. During his tenure at Pfizer, Mr. Nicholson served on the board of directors of the Pfizer Foundation and was a member of the company's Portfolio, Strategy and Investment Committee, which set corporate research and development priorities and investment strategy. Mr. Nicholson received a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina.

Scott Garland: Scott Garland，自2024年2月起担任董事会主席。自2023年9月以来，Garland先生一直是Vida Ventures的合伙人。Garland先生曾担任PACT Pharma，Inc.的首席执行官，该公司是一家免疫肿瘤学公司，2021年至2023年专注于为实体瘤开发新抗原靶向T细胞疗法。在加入PACT Pharmaceuticals，Inc.之前，Garland先生于2018年至2020年担任波尔图制药公司的总裁兼首席执行官，在那里他领导公司完成了Andexxa的商业启动和被亚力兄制药公司制药公司的收购。在加入丨Portola Pharmaceuticals，Inc. Portola Pharmaceuticals, Inc.之前，Garland先生于2014年至2018年在RelypsaTERM1 Inc.担任首席商务官，在Relypsa Inc.被Vifor Pharma AG收购后担任该美国组织的总裁。在加入Relypsa公司之前，Garland先生于2011年至2014年担任伊克力西斯公司的首席商务官。加兰先生还曾在基因泰克、安进公司、默克制药公司担任过许多其他商业领导职务，包括领导两种价值数十亿美元疗法——阿瓦斯汀和美罗华的商业特许经营权。他还自2022年11月起担任生物制药公司ALX Oncology Inc.的董事会成员，自2021年8月起担任生物制药公司Day One Biopharmaceuticals, Inc.，自2023年10月起担任生物制药公司Olema Pharmaceuticals, Inc.的董事会成员。Garland先生于2014年至2020年在生物技术公司Karyopharm Therapeutics Inc.的董事会任职，并于2020年至2023年在Calithera生物科学公司的董事会任职。Garland先生获得了加州理工州立大学-San Luis Obispo的理学学士学位和杜克大学Fuqua商学院的工商管理硕士学位。

Scott Garland has served as Chairman of Lb Pharmaceuticals Inc's board of directors since February 2024. Since September 2023, Mr. Garland has been an advisor at Google Ventures. Mr. Garland was the Chief Executive Officer of PACT Pharma, Inc., an immuno oncology company focused on developing neoantigen targeted T cell therapies for solid tumors from 2021 to 2023. Prior to PACT Pharma, Inc., Mr. Garland served as President and Chief Executive Officer of Portola Pharmaceuticals, Inc. from 2018 to 2020, where he led the company through the commercial launch of Andexxa and acquisition by Alexion Pharmaceuticals, Inc. Before joining Portola Pharmaceuticals, Inc., Mr. Garland was at Relypsa Inc. from 2014 to 2018, where he served as Chief Commercial Officer, and then as President of the U.S. organization after Relypsa Inc.'s acquisition by Vifor Pharma AG. Prior to Relypsa Inc., Mr. Garland was Chief Commercial Officer at Exelixis, Inc. from 2011 to 2014. Mr. Garland has held numerous other commercial leadership roles at Genentech, Inc., Amgen Inc., Merck & Co., Inc., including leading the commercial franchises for two multi billion dollar therapies—Avastin and Rituxan. He also serves as a board member for ALX Oncology Inc., a biopharmaceutical company, since November 2022, and Day One Biopharmaceuticals, Inc., a biopharmaceutical company, since August 2021, and Olema Pharmaceuticals, Inc., a biopharmaceutical company, since October 2023. Mr. Garland served on the Board of Directors for Karyopharm Therapeutics Inc., a biotechnology company, from 2014 to 2020 and on the Board of Directors of Calithera Biosciences, Inc. from 2020 to 2023. Mr. Garland received a Bachelor of Science degree from California Polytechnic State University San Luis Obispo and a master's degree in Business Administration from the Fuqua School of Business at Duke University.; Scott Garland，自2024年2月起担任董事会主席。自2023年9月以来，Garland先生一直是Vida Ventures的合伙人。Garland先生曾担任PACT Pharma，Inc.的首席执行官，该公司是一家免疫肿瘤学公司，2021年至2023年专注于为实体瘤开发新抗原靶向T细胞疗法。在加入PACT Pharmaceuticals，Inc.之前，Garland先生于2018年至2020年担任波尔图制药公司的总裁兼首席执行官，在那里他领导公司完成了Andexxa的商业启动和被亚力兄制药公司制药公司的收购。在加入丨Portola Pharmaceuticals，Inc. Portola Pharmaceuticals, Inc.之前，Garland先生于2014年至2018年在RelypsaTERM1 Inc.担任首席商务官，在Relypsa Inc.被Vifor Pharma AG收购后担任该美国组织的总裁。在加入Relypsa公司之前，Garland先生于2011年至2014年担任伊克力西斯公司的首席商务官。加兰先生还曾在基因泰克、安进公司、默克制药公司担任过许多其他商业领导职务，包括领导两种价值数十亿美元疗法——阿瓦斯汀和美罗华的商业特许经营权。他还自2022年11月起担任生物制药公司ALX Oncology Inc.的董事会成员，自2021年8月起担任生物制药公司Day One Biopharmaceuticals, Inc.，自2023年10月起担任生物制药公司Olema Pharmaceuticals, Inc.的董事会成员。Garland先生于2014年至2020年在生物技术公司Karyopharm Therapeutics Inc.的董事会任职，并于2020年至2023年在Calithera生物科学公司的董事会任职。Garland先生获得了加州理工州立大学-San Luis Obispo的理学学士学位和杜克大学Fuqua商学院的工商管理硕士学位。; Scott Garland has served as Chairman of Lb Pharmaceuticals Inc's board of directors since February 2024. Since September 2023, Mr. Garland has been an advisor at Google Ventures. Mr. Garland was the Chief Executive Officer of PACT Pharma, Inc., an immuno oncology company focused on developing neoantigen targeted T cell therapies for solid tumors from 2021 to 2023. Prior to PACT Pharma, Inc., Mr. Garland served as President and Chief Executive Officer of Portola Pharmaceuticals, Inc. from 2018 to 2020, where he led the company through the commercial launch of Andexxa and acquisition by Alexion Pharmaceuticals, Inc. Before joining Portola Pharmaceuticals, Inc., Mr. Garland was at Relypsa Inc. from 2014 to 2018, where he served as Chief Commercial Officer, and then as President of the U.S. organization after Relypsa Inc.'s acquisition by Vifor Pharma AG. Prior to Relypsa Inc., Mr. Garland was Chief Commercial Officer at Exelixis, Inc. from 2011 to 2014. Mr. Garland has held numerous other commercial leadership roles at Genentech, Inc., Amgen Inc., Merck & Co., Inc., including leading the commercial franchises for two multi billion dollar therapies—Avastin and Rituxan. He also serves as a board member for ALX Oncology Inc., a biopharmaceutical company, since November 2022, and Day One Biopharmaceuticals, Inc., a biopharmaceutical company, since August 2021, and Olema Pharmaceuticals, Inc., a biopharmaceutical company, since October 2023. Mr. Garland served on the Board of Directors for Karyopharm Therapeutics Inc., a biotechnology company, from 2014 to 2020 and on the Board of Directors of Calithera Biosciences, Inc. from 2020 to 2023. Mr. Garland received a Bachelor of Science degree from California Polytechnic State University San Luis Obispo and a master's degree in Business Administration from the Fuqua School of Business at Duke University.

Habib Dable: Habib Dable，目前是RA Capital Management，L.P.的顾问。最近，Dable先生曾担任Acceleron Pharma Inc.的总裁兼首席执行官，该公司是一家生物制药公司，致力于为患有严重和罕见疾病的患者提供前沿疗法，直到2021年被默沙东收购。在2016年加入Acceleron之前，Dable先生在拜耳公司工作了22年，曾担任美国制药公司总裁；全球头部专科医学执行副总裁；眼科副总裁；EYLEA全球发射团队负责人；全球主管，神经病学和眼科；副总裁，区域主管，血液学和心脏病学。他还在Day One生物制药、PepGen公司和BioLink.org的董事会任职。Dable先生还是蓝图医药、Millendo Therapeutics、Aerovate Therapeutics和Albireo Pharma的前董事会成员。Dable先生获得了新布朗斯威克大学的B.B.A和M.B.A.学位。

Habib Dable,is currently an advisor at RA Capital Management, L.P. Most recently, Mr. Dable was President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company targeting leading-edge therapies for patients with serious and rare diseases, until its acquisition by Merck in 2021. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG where he served as President of U.S. Pharmaceuticals; Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology; Global Launch Team Head, EYLEA; Global Head, Neurology and Ophthalmology; and Vice President, Regional Head, Hematology and Cardiology. He also serves on the board of directors of Day One Biopharmaceuticals, PepGen Inc. and BioLink.org. Mr. Dable is also a former member of the board of directors of Blueprint Medicines, Millendo Therapeutics, Aerovate Therapeutics and Albireo Pharma. Mr. Dable received a B.B.A and M.B.A. from the University of New Brunswick.; Habib Dable，目前是RA Capital Management，L.P.的顾问。最近，Dable先生曾担任Acceleron Pharma Inc.的总裁兼首席执行官，该公司是一家生物制药公司，致力于为患有严重和罕见疾病的患者提供前沿疗法，直到2021年被默沙东收购。在2016年加入Acceleron之前，Dable先生在拜耳公司工作了22年，曾担任美国制药公司总裁；全球头部专科医学执行副总裁；眼科副总裁；EYLEA全球发射团队负责人；全球主管，神经病学和眼科；副总裁，区域主管，血液学和心脏病学。他还在Day One生物制药、PepGen公司和BioLink.org的董事会任职。Dable先生还是蓝图医药、Millendo Therapeutics、Aerovate Therapeutics和Albireo Pharma的前董事会成员。Dable先生获得了新布朗斯威克大学的B.B.A和M.B.A.学位。; Habib Dable,is currently an advisor at RA Capital Management, L.P. Most recently, Mr. Dable was President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company targeting leading-edge therapies for patients with serious and rare diseases, until its acquisition by Merck in 2021. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG where he served as President of U.S. Pharmaceuticals; Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology; Global Launch Team Head, EYLEA; Global Head, Neurology and Ophthalmology; and Vice President, Regional Head, Hematology and Cardiology. He also serves on the board of directors of Day One Biopharmaceuticals, PepGen Inc. and BioLink.org. Mr. Dable is also a former member of the board of directors of Blueprint Medicines, Millendo Therapeutics, Aerovate Therapeutics and Albireo Pharma. Mr. Dable received a B.B.A and M.B.A. from the University of New Brunswick.

Garry Nicholson: Garry Nicholson自2022年9月起担任Day One Biopharmaceuticals, Inc.董事会主席。2015年8月至2016年10月，他担任XTuit Pharmaceuticals，Inc.的总裁兼首席执行官，同时也是该公司的董事会成员。Nicholson先生于2008年5月加入辉瑞，领导全球肿瘤学特许经营，并于2015年4月在那里结束了他的职业生涯，担任辉瑞肿瘤学总裁。在辉瑞任职期间，Nicholson先生曾担任辉瑞基金会的董事会成员，并且是公司投资组合、战略和投资委员会的成员，该委员会负责制定企业研发重点和投资战略。Nicholson先生获得了北卡罗来纳大学教堂山分校的药学学士学位和南卡罗来纳大学的工商管理硕士学位。Day One BioPharmaceuticals，Inc.认为Nicholson先生有资格在Day One Biopharmaceuticals, Inc.董事会任职，因为他在生物制药行业拥有丰富的领导历史以及广泛的经验。

Garry Nicholson has served as chair of Day One Biopharmaceuticals, Inc.'s board of directors since September 2022. From August 2015 to October 2016 he served as President and Chief Executive Officer of XTuit Pharmaceuticals, Inc., where he was also a member of the board of directors. Mr. Nicholson joined Pfizer, Inc. in May 2008 to lead the global oncology franchise, finishing his career there as President, Pfizer Oncology in April 2015. During his tenure at Pfizer, Mr. Nicholson served on the board of directors of the Pfizer Foundation and was a member of the company's Portfolio, Strategy and Investment Committee, which set corporate research and development priorities and investment strategy. Mr. Nicholson received a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina. Day One Biopharmaceuticals, Inc.; Garry Nicholson自2022年9月起担任Day One Biopharmaceuticals, Inc.董事会主席。2015年8月至2016年10月，他担任XTuit Pharmaceuticals，Inc.的总裁兼首席执行官，同时也是该公司的董事会成员。Nicholson先生于2008年5月加入辉瑞，领导全球肿瘤学特许经营，并于2015年4月在那里结束了他的职业生涯，担任辉瑞肿瘤学总裁。在辉瑞任职期间，Nicholson先生曾担任辉瑞基金会的董事会成员，并且是公司投资组合、战略和投资委员会的成员，该委员会负责制定企业研发重点和投资战略。Nicholson先生获得了北卡罗来纳大学教堂山分校的药学学士学位和南卡罗来纳大学的工商管理硕士学位。Day One BioPharmaceuticals，Inc.认为Nicholson先生有资格在Day One Biopharmaceuticals, Inc.董事会任职，因为他在生物制药行业拥有丰富的领导历史以及广泛的经验。; Garry Nicholson has served as chair of Day One Biopharmaceuticals, Inc.'s board of directors since September 2022. From August 2015 to October 2016 he served as President and Chief Executive Officer of XTuit Pharmaceuticals, Inc., where he was also a member of the board of directors. Mr. Nicholson joined Pfizer, Inc. in May 2008 to lead the global oncology franchise, finishing his career there as President, Pfizer Oncology in April 2015. During his tenure at Pfizer, Mr. Nicholson served on the board of directors of the Pfizer Foundation and was a member of the company's Portfolio, Strategy and Investment Committee, which set corporate research and development priorities and investment strategy. Mr. Nicholson received a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina. Day One Biopharmaceuticals, Inc.

Habib Dable: Habib Dable自2024年1月起担任董事会成员。Dable先生自2022年4月起担任RA Capital Management，L.P.的兼职顾问，该公司是一家多阶段投资管理公司，投资于公立和私立医疗保健以及生命科学公司，此前曾于2016年12月至2021年11月期间担任生物制药公司Acceleron Pharma Inc.的总裁兼首席执行官，当时该公司被默沙东收购。在2016年加入Acceleron之前，Dable先生曾在拜耳集团担任美国制药公司总裁。在达布尔任职的22年期间，他担任的职务责任越来越大。除美国制药总裁外，他还担任执行副总裁，全球头部专科医学；眼科副总裁，全球发射团队负责人，EYLEA，全球主管，神经病学和眼科，副总裁，区域主管，血液学和心脏病学。Dable先生早先在拜耳集团的经历包括在美国、日本和加拿大的各种战略和商业职位。Dable先生分别自2026年2月、2025年11月和2022年9月起担任Spyglass Therapeutics，Inc.、Relay Therapeutics，Inc.和PepGen Inc.的董事会成员。此前曾于2022年6月至2025年7月担任蓝图医药公司董事会成员，于2023年7月至2025年4月担任Aerovate Therapeutics，Inc.董事会成员，于2022年8月至2023年3月担任Albireo Pharma，Inc.董事会成员。Dable先生获得了加拿大新布鲁斯威克大学布朗斯威克的学士和工商管理硕士学位。Day One Biopharmaceuticals，Inc.认为Dable先生有资格在Day One Biopharmaceuticals, Inc.董事会任职，因为他在生物技术行业拥有丰富的运营和商业经验。

Habib Dable has served as a member of board of directors since January 2024. Mr. Dable serves as a part time advisor at RA Capital Management, L.P., a multi stage investment management firm that invests in public and private healthcare and life science companies, since April 2022 and previously served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 to November 2021, when it was acquired by Merck. Prior to joining Acceleron in 2016, Mr. Dable served as President of U.S. Pharmaceuticals at Bayer AG. During his 22 year tenure there, Mr. Dable held positions of increasing responsibility. In addition to President of U.S. Pharmaceuticals, he also served as Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology, Global Launch Team Head, EYLEA, Global Head, Neurology and Ophthalmology and Vice President, Regional Head, Hematology and Cardiology. Mr. Dable's earlier experience at Bayer AG includes various strategic and commercial positions in the USA, Japan and Canada. Mr. Dable has served on the board of directors of Spyglass Therapeutics, Inc., Relay Therapeutics, Inc. and PepGen Inc. since February 2026, November 2025 and September 2022, respectively. He previously served on the board of directors of Blueprint Medicines Corp. from June 2022 to July 2025, Aerovate Therapeutics, Inc. from July 2023 to April 2025, and Albireo Pharma, Inc. from August 2022 to March 2023. Mr. Dable received a B.B.A. and M.B.A. from the University of New Brunswick in Canada. Day One Biopharmaceuticals, Inc. believe Mr. Dable is qualified to serve on Day One Biopharmaceuticals, Inc.'s board of directors because of his extensive operational and commercial experience in the biotechnology industry.; Habib Dable自2024年1月起担任董事会成员。Dable先生自2022年4月起担任RA Capital Management，L.P.的兼职顾问，该公司是一家多阶段投资管理公司，投资于公立和私立医疗保健以及生命科学公司，此前曾于2016年12月至2021年11月期间担任生物制药公司Acceleron Pharma Inc.的总裁兼首席执行官，当时该公司被默沙东收购。在2016年加入Acceleron之前，Dable先生曾在拜耳集团担任美国制药公司总裁。在达布尔任职的22年期间，他担任的职务责任越来越大。除美国制药总裁外，他还担任执行副总裁，全球头部专科医学；眼科副总裁，全球发射团队负责人，EYLEA，全球主管，神经病学和眼科，副总裁，区域主管，血液学和心脏病学。Dable先生早先在拜耳集团的经历包括在美国、日本和加拿大的各种战略和商业职位。Dable先生分别自2026年2月、2025年11月和2022年9月起担任Spyglass Therapeutics，Inc.、Relay Therapeutics，Inc.和PepGen Inc.的董事会成员。此前曾于2022年6月至2025年7月担任蓝图医药公司董事会成员，于2023年7月至2025年4月担任Aerovate Therapeutics，Inc.董事会成员，于2022年8月至2023年3月担任Albireo Pharma，Inc.董事会成员。Dable先生获得了加拿大新布鲁斯威克大学布朗斯威克的学士和工商管理硕士学位。Day One Biopharmaceuticals，Inc.认为Dable先生有资格在Day One Biopharmaceuticals, Inc.董事会任职，因为他在生物技术行业拥有丰富的运营和商业经验。; Habib Dable has served as a member of board of directors since January 2024. Mr. Dable serves as a part time advisor at RA Capital Management, L.P., a multi stage investment management firm that invests in public and private healthcare and life science companies, since April 2022 and previously served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 to November 2021, when it was acquired by Merck. Prior to joining Acceleron in 2016, Mr. Dable served as President of U.S. Pharmaceuticals at Bayer AG. During his 22 year tenure there, Mr. Dable held positions of increasing responsibility. In addition to President of U.S. Pharmaceuticals, he also served as Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology, Global Launch Team Head, EYLEA, Global Head, Neurology and Ophthalmology and Vice President, Regional Head, Hematology and Cardiology. Mr. Dable's earlier experience at Bayer AG includes various strategic and commercial positions in the USA, Japan and Canada. Mr. Dable has served on the board of directors of Spyglass Therapeutics, Inc., Relay Therapeutics, Inc. and PepGen Inc. since February 2026, November 2025 and September 2022, respectively. He previously served on the board of directors of Blueprint Medicines Corp. from June 2022 to July 2025, Aerovate Therapeutics, Inc. from July 2023 to April 2025, and Albireo Pharma, Inc. from August 2022 to March 2023. Mr. Dable received a B.B.A. and M.B.A. from the University of New Brunswick in Canada. Day One Biopharmaceuticals, Inc. believe Mr. Dable is qualified to serve on Day One Biopharmaceuticals, Inc.'s board of directors because of his extensive operational and commercial experience in the biotechnology industry.

Scott Garland: Scott Garland自2021年8月起担任Day One Biopharmaceuticals, Inc.董事会成员。Garland先生于2021年3月至2023年2月担任免疫肿瘤公司PACT Pharma，Inc.的首席执行官。在加入PACT之前，Garland先生是波尔图制药，Inc.的总裁、首席执行官和董事会成员，此前该公司于2020年7月与亚力兄制药制药公司合并。在加入Portola之前，Garland先生于2017年4月至2018年10月担任生物制药公司Relypsa公司总裁，并于2014年11月至2017年4月担任高级副总裁兼首席商务官。2011年10月至2014年10月，Garland先生担任Exelixis, Inc.的执行副总裁兼首席商务官，该公司是一家专注于癌症治疗药物的开发和商业化的生物制药公司。从2002年4月到2011年10月，Garland先生曾在生物制药公司基因泰克任职，最近担任基因泰克的阿瓦斯汀副总裁特许经营权，在那里他领导了该药物在美国的销售和营销工作。在担任该职位之前，他曾担任副总裁，血液学营销和销售，监督Rituxan特许经营和作为营销总监在特罗凯专营权。从1997年7月至2002年4月，Garland先生曾在生物技术公司安进公司的销售和营销部门担任多个职务。从1991年7月至1995年7月，他在生物制药公司默克制药公司担任专业销售代表。Garland先生自2022年11月起担任ALX Oncology Holdings Inc.董事会董事、自2023年10月起担任Olema Pharmaceuticals，Inc.董事会董事、自2024年3月起担任LB Pharmaceuticals Inc.董事会董事、自2025年9月起担任Hexagon Bio Inc.董事会董事、自2026年1月起担任Enliven Therapeutics，Inc.董事会董事。Garland先生此前曾于2014年11月至2020年6月担任Karyopharm Therapeutics，Inc.的董事会成员，并于2020年7月至2023年12月担任Calithera生物科学 Biosciences，Inc.的董事会成员。Garland先生拥有杜克大学Fuqua商学院的工商管理硕士学位和加州理工大学（San Luis Obispo）的学士学位。Day One Biopharmaceuticals，Inc.认为，由于Garland先生在生物制药行业的经验以及他的商业和执行领导经验，他有资格在Day One Biopharmaceuticals, Inc.董事会任职。

Scott Garland has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since August 2021. Mr. Garland was Chief Executive Officer of PACT Pharma, Inc., an immune oncology company, from March 2021 to February 2023. Prior to joining PACT, Mr. Garland was President, CEO and a member of the board of Portola Pharmaceuticals, Inc. prior to its merger with Alexion Pharmaceuticals, Inc. in July 2020. Prior to Portola, Mr. Garland served as President of Relypsa Inc., a biopharmaceutical company, from April 2017 to October 2018, and as Senior Vice President and Chief Commercial Officer from November 2014 to April 2017. From October 2011 to October 2014, Mr. Garland served as Executive Vice President and Chief Commercial Officer of Exelixis, Inc., a biopharmaceutical company focused on developing and commercializing cancer treatments. From April 2002 to October 2011, Mr. Garland held positions at Genentech, Inc., a biopharmaceutical company, most recently serving as Vice President of Genentech's Avastin franchise, where he led the U.S. sales and marketing efforts for the drug. Prior to that position, he served as Vice President, Hematology Marketing and Sales, overseeing the Rituxan franchise and as a Marketing Director on the Tarceva franchise. From July 1997 to April 2002, Mr. Garland held several positions within the sales and marketing division of Amgen, Inc., a biotechnology company, and from July 1991 to July 1995, he served as a professional sales representative at Merck & Co., Inc., a biopharmaceutical company. Mr. Garland serves on the board of directors of ALX Oncology Holdings Inc. since November 2022, Olema Pharmaceuticals, Inc. since October 2023, LB Pharmaceuticals Inc. since March 2024, Hexagon Bio Inc. since September 2025 and Enliven Therapeutics, Inc. since January 2026. Mr. Garland previously served on the board of directors of Karyopharm Therapeutics, Inc., from November 2014 to June 2020 and Calithera Biosciences, Inc. from July 2020 to December 2023. Mr. Garland holds an M.B.A. from Duke University's Fuqua School of Business and a B.S. from California Polytechnic University (San Luis Obispo). Day One Biopharmaceuticals, Inc. believe Mr. Garland is qualified to serve on Day One Biopharmaceuticals, Inc.'s board of directors because of his experience in the biopharmaceutical industry and his commercial and executive leadership experience.; Scott Garland自2021年8月起担任Day One Biopharmaceuticals, Inc.董事会成员。Garland先生于2021年3月至2023年2月担任免疫肿瘤公司PACT Pharma，Inc.的首席执行官。在加入PACT之前，Garland先生是波尔图制药，Inc.的总裁、首席执行官和董事会成员，此前该公司于2020年7月与亚力兄制药制药公司合并。在加入Portola之前，Garland先生于2017年4月至2018年10月担任生物制药公司Relypsa公司总裁，并于2014年11月至2017年4月担任高级副总裁兼首席商务官。2011年10月至2014年10月，Garland先生担任Exelixis, Inc.的执行副总裁兼首席商务官，该公司是一家专注于癌症治疗药物的开发和商业化的生物制药公司。从2002年4月到2011年10月，Garland先生曾在生物制药公司基因泰克任职，最近担任基因泰克的阿瓦斯汀副总裁特许经营权，在那里他领导了该药物在美国的销售和营销工作。在担任该职位之前，他曾担任副总裁，血液学营销和销售，监督Rituxan特许经营和作为营销总监在特罗凯专营权。从1997年7月至2002年4月，Garland先生曾在生物技术公司安进公司的销售和营销部门担任多个职务。从1991年7月至1995年7月，他在生物制药公司默克制药公司担任专业销售代表。Garland先生自2022年11月起担任ALX Oncology Holdings Inc.董事会董事、自2023年10月起担任Olema Pharmaceuticals，Inc.董事会董事、自2024年3月起担任LB Pharmaceuticals Inc.董事会董事、自2025年9月起担任Hexagon Bio Inc.董事会董事、自2026年1月起担任Enliven Therapeutics，Inc.董事会董事。Garland先生此前曾于2014年11月至2020年6月担任Karyopharm Therapeutics，Inc.的董事会成员，并于2020年7月至2023年12月担任Calithera生物科学 Biosciences，Inc.的董事会成员。Garland先生拥有杜克大学Fuqua商学院的工商管理硕士学位和加州理工大学（San Luis Obispo）的学士学位。Day One Biopharmaceuticals，Inc.认为，由于Garland先生在生物制药行业的经验以及他的商业和执行领导经验，他有资格在Day One Biopharmaceuticals, Inc.董事会任职。; Scott Garland has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since August 2021. Mr. Garland was Chief Executive Officer of PACT Pharma, Inc., an immune oncology company, from March 2021 to February 2023. Prior to joining PACT, Mr. Garland was President, CEO and a member of the board of Portola Pharmaceuticals, Inc. prior to its merger with Alexion Pharmaceuticals, Inc. in July 2020. Prior to Portola, Mr. Garland served as President of Relypsa Inc., a biopharmaceutical company, from April 2017 to October 2018, and as Senior Vice President and Chief Commercial Officer from November 2014 to April 2017. From October 2011 to October 2014, Mr. Garland served as Executive Vice President and Chief Commercial Officer of Exelixis, Inc., a biopharmaceutical company focused on developing and commercializing cancer treatments. From April 2002 to October 2011, Mr. Garland held positions at Genentech, Inc., a biopharmaceutical company, most recently serving as Vice President of Genentech's Avastin franchise, where he led the U.S. sales and marketing efforts for the drug. Prior to that position, he served as Vice President, Hematology Marketing and Sales, overseeing the Rituxan franchise and as a Marketing Director on the Tarceva franchise. From July 1997 to April 2002, Mr. Garland held several positions within the sales and marketing division of Amgen, Inc., a biotechnology company, and from July 1991 to July 1995, he served as a professional sales representative at Merck & Co., Inc., a biopharmaceutical company. Mr. Garland serves on the board of directors of ALX Oncology Holdings Inc. since November 2022, Olema Pharmaceuticals, Inc. since October 2023, LB Pharmaceuticals Inc. since March 2024, Hexagon Bio Inc. since September 2025 and Enliven Therapeutics, Inc. since January 2026. Mr. Garland previously served on the board of directors of Karyopharm Therapeutics, Inc., from November 2014 to June 2020 and Calithera Biosciences, Inc. from July 2020 to December 2023. Mr. Garland holds an M.B.A. from Duke University's Fuqua School of Business and a B.S. from California Polytechnic University (San Luis Obispo). Day One Biopharmaceuticals, Inc. believe Mr. Garland is qualified to serve on Day One Biopharmaceuticals, Inc.'s board of directors because of his experience in the biopharmaceutical industry and his commercial and executive leadership experience.

William Grossman: William Grossman自2024年1月起担任Day One Biopharmaceuticals, Inc.董事会成员。Grossman博士目前担任制药药物开发公司Oncko，Inc.的联合创始人和研发主管，自2024年11月起。自2019年2月以来，他还是Grossman Biotech & Pharma Consulting，LLC的创始人，该公司是一家向生物技术和风险投资/私募股权组织提供部分CMO服务的咨询公司。此前，他曾于2021年8月至2024年8月在生物制药公司吉利德科学公司担任高级副总裁兼临床开发肿瘤治疗领域负责人。在此之前，他于2019年4月至2021年8月在Arcus Biosciences，Inc.担任首席医疗官，于2018年2月至2019年4月在Bellicum制药，Inc.担任首席医疗官。2008年至2018年期间，他还曾在默沙东、百特国际有限公司、Bio Thera Solutions Inc.、艾伯维公司和基因泰克/罗氏公司担任其他领导职务。他还曾在威斯康辛州儿童医院/威斯康辛州医学院担任临床免疫诊断和研究实验室的创始人和医学主任，2004年至2008年担任微生物学和遗传学教授以及免疫缺陷移植项目骨髓移植部主任。Grossman博士自2025年7月起担任enGene Holdings Inc.董事会成员。Grossman博士在华盛顿大学医学院的医学科学家培训计划中获得了免疫学的医学博士和博士学位，并在华盛顿大学医学院的儿科和医学部完成了医学和博士后培训。Day One BioPharmaceuticals，Inc.认为Grossman博士有资格在Day One Biopharmaceuticals, Inc.董事会任职，因为他在生物技术行业接受过医学培训和丰富的领导经验。

William Grossman has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since January 2024. Dr. Grossman currently serves as Co Founder and Head of Research & Development of Oncko, Inc., a pharmaceutical drug development company, since November 2024. He is also the Founder of Grossman Biotech & Pharma Consulting, LLC, a consulting firm which offers fractional CMO services to biotechnology and venture capital/private equity organizations, since February 2019. Previously, he served as Senior Vice President and Oncology Therapeutic Area Head of Clinical Development at Gilead Sciences, Inc., a biopharmaceutical company, from August 2021 to August 2024. Prior to that, he held Chief Medical Officer roles at Arcus Biosciences, Inc. from April 2019 to August 2021 and Bellicum Pharmaceuticals, Inc. from February 2018 to April 2019. He has held additional leadership roles at Merck & Co., Baxter International Inc., Bio Thera Solutions Inc., AbbVie Inc. and Genentech/Roche between 2008 and 2018. He also served at the Children's Hospital of Wisconsin/Medical College of Wisconsin as Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics and Director of the Bone Marrow Transplant Division for the Immunodeficiency Transplant Program from 2004 to 2008. Dr. Grossman has served on the board of directors of enGene Holdings Inc. since July 2025. Dr. Grossman received his M.D. and Ph.D. in Immunology from Washington University School of Medicine's Medical Scientist Training Program and completed his medical and postdoctoral training in the Divisions of Pediatrics and Medicine at Washington University School of Medicine. Day One Biopharmaceuticals, Inc. believe Dr. Grossman is qualified to serve on Day One Biopharmaceuticals, Inc.'s board of directors because of his medical training and extensive leadership experience in the biotechnology industry.; William Grossman自2024年1月起担任Day One Biopharmaceuticals, Inc.董事会成员。Grossman博士目前担任制药药物开发公司Oncko，Inc.的联合创始人和研发主管，自2024年11月起。自2019年2月以来，他还是Grossman Biotech & Pharma Consulting，LLC的创始人，该公司是一家向生物技术和风险投资/私募股权组织提供部分CMO服务的咨询公司。此前，他曾于2021年8月至2024年8月在生物制药公司吉利德科学公司担任高级副总裁兼临床开发肿瘤治疗领域负责人。在此之前，他于2019年4月至2021年8月在Arcus Biosciences，Inc.担任首席医疗官，于2018年2月至2019年4月在Bellicum制药，Inc.担任首席医疗官。2008年至2018年期间，他还曾在默沙东、百特国际有限公司、Bio Thera Solutions Inc.、艾伯维公司和基因泰克/罗氏公司担任其他领导职务。他还曾在威斯康辛州儿童医院/威斯康辛州医学院担任临床免疫诊断和研究实验室的创始人和医学主任，2004年至2008年担任微生物学和遗传学教授以及免疫缺陷移植项目骨髓移植部主任。Grossman博士自2025年7月起担任enGene Holdings Inc.董事会成员。Grossman博士在华盛顿大学医学院的医学科学家培训计划中获得了免疫学的医学博士和博士学位，并在华盛顿大学医学院的儿科和医学部完成了医学和博士后培训。Day One BioPharmaceuticals，Inc.认为Grossman博士有资格在Day One Biopharmaceuticals, Inc.董事会任职，因为他在生物技术行业接受过医学培训和丰富的领导经验。; William Grossman has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since January 2024. Dr. Grossman currently serves as Co Founder and Head of Research & Development of Oncko, Inc., a pharmaceutical drug development company, since November 2024. He is also the Founder of Grossman Biotech & Pharma Consulting, LLC, a consulting firm which offers fractional CMO services to biotechnology and venture capital/private equity organizations, since February 2019. Previously, he served as Senior Vice President and Oncology Therapeutic Area Head of Clinical Development at Gilead Sciences, Inc., a biopharmaceutical company, from August 2021 to August 2024. Prior to that, he held Chief Medical Officer roles at Arcus Biosciences, Inc. from April 2019 to August 2021 and Bellicum Pharmaceuticals, Inc. from February 2018 to April 2019. He has held additional leadership roles at Merck & Co., Baxter International Inc., Bio Thera Solutions Inc., AbbVie Inc. and Genentech/Roche between 2008 and 2018. He also served at the Children's Hospital of Wisconsin/Medical College of Wisconsin as Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics and Director of the Bone Marrow Transplant Division for the Immunodeficiency Transplant Program from 2004 to 2008. Dr. Grossman has served on the board of directors of enGene Holdings Inc. since July 2025. Dr. Grossman received his M.D. and Ph.D. in Immunology from Washington University School of Medicine's Medical Scientist Training Program and completed his medical and postdoctoral training in the Divisions of Pediatrics and Medicine at Washington University School of Medicine. Day One Biopharmaceuticals, Inc. believe Dr. Grossman is qualified to serve on Day One Biopharmaceuticals, Inc.'s board of directors because of his medical training and extensive leadership experience in the biotechnology industry.

Saira Ramasastry: Saira Ramasastry，2013年2月起担任董事。2013年之前，她是本公司的顾问。她从2009年起，担任Life Sciences Advisory, LLC的管理合伙人，这是一个生命科学行业的咨询公司。1999-2009，她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998，她是投资银行公司Wasserstein Perella & Co.并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事，是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员，也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位，并在 University of Cambridge获得管理研究的学术硕士学位。

Saira Ramasastry has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since March 2021. Ms. Ramasastry is the Managing Partner of Life Sciences Advisory, LLC, since April 2009, a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life sciences industry. She has also served as Co Founder and Chief Operating Officer of Sanacor Inc. since April 2022. From August 1999 to March 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry has served on the boards of directors of Vir Biotechnology, Inc., since September 2019, Glenmark Pharmaceuticals, Ltd., since April 2019, and Mirum Pharmaceuticals, Inc., since June 2022. Ms. Ramasastry previously served on the board of directors of Akouos, Inc. from 2020 until it was acquired by Eli Lilly & Company in December 2022, and Sangamo Therapeutics from June 2012 until May 2022. Ms. Ramasastry received her B.A. in Economics with honors and distinction and an M.S. in Management Science and Engineering from Stanford University, as well as an M. Phil. in Management Studies from the University of Cambridge where she is a guest lecturer for the Masters of Bioscience Enterprise Programme. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. Day One Biopharmaceuticals, Inc.; Saira Ramasastry，2013年2月起担任董事。2013年之前，她是本公司的顾问。她从2009年起，担任Life Sciences Advisory, LLC的管理合伙人，这是一个生命科学行业的咨询公司。1999-2009，她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998，她是投资银行公司Wasserstein Perella & Co.并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事，是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员，也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位，并在 University of Cambridge获得管理研究的学术硕士学位。; Saira Ramasastry has served as a member of Day One Biopharmaceuticals, Inc.'s board of directors since March 2021. Ms. Ramasastry is the Managing Partner of Life Sciences Advisory, LLC, since April 2009, a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life sciences industry. She has also served as Co Founder and Chief Operating Officer of Sanacor Inc. since April 2022. From August 1999 to March 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry has served on the boards of directors of Vir Biotechnology, Inc., since September 2019, Glenmark Pharmaceuticals, Ltd., since April 2019, and Mirum Pharmaceuticals, Inc., since June 2022. Ms. Ramasastry previously served on the board of directors of Akouos, Inc. from 2020 until it was acquired by Eli Lilly & Company in December 2022, and Sangamo Therapeutics from June 2012 until May 2022. Ms. Ramasastry received her B.A. in Economics with honors and distinction and an M.S. in Management Science and Engineering from Stanford University, as well as an M. Phil. in Management Studies from the University of Cambridge where she is a guest lecturer for the Masters of Bioscience Enterprise Programme. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. Day One Biopharmaceuticals, Inc.

高管简历

中英对照 | 中文 | 英文

Michael Vasconcelles: Michael Vasconcelles，自2020年4月起担任Molecular Partners AG董事。他目前是Flatiron Health，Inc.的首席医疗官，在战略规划、思想领导和临床研究方法方面拥有专业知识。在2019年加入Flatiron Health之前，Vasconcelles博士在2015年至2019年期间担任联合国大学治疗学公司的首席医疗官。在联合国大学之前，他在武田/千禧大学工作了几年，负责研究和发展战略以及执行肿瘤学组合，从发现到产品许可和后期批准。Vasconcelles博士于1996年加入哈佛医学院，目前是哈佛医学院的临床医学讲师，也是Dana Farber癌症研究所和波士顿Brigham&Women医院的执业肿瘤学家和副医师。Vasconcelles博士是众多专业协会的成员，包括美国临床肿瘤学会和美国血液学学会。他的董事会承诺包括个性化医疗联盟和美国癌症协会的东新英格兰董事会。Vasconcelles博士完成了贝斯以色列医院内科学研究生培训和布里格姆女子医院血液肿瘤学研究，并从西北大学获得B.A。和M.D。

Michael Vasconcelles has served as a director since April 2020. He currently serves as head of research and development at Day One BioPharmaceuticals since June 2025. Previoly, he was executive vice president, Research, Development, and Medical Affairs at Immunogen from December 2022 until its acquisition by AbbVie in February 2024. Prior to Immunogen, he was chief medical officer and head of the Medical and Scientific Organization at Flatiron Health, a healthcare technology and services company foced on creating digital solutions to accelerate cancer research and improve patient care, from August 2019 to August 2022. Prior to joining Flatiron Health, Dr. Vasconcelles served as the chief medical officer of Unum Therapeutics Inc. (Unum) from October 2015 to July 2019, a Cambridge, MA based cell and gene therapy company. Prior to Unum, Dr. Vasconcelles spent several years at Takeda/Millennium, where he was senior vice president, Head of the Oncology Therapy Area Unit and member of the R&D Executive Team, accountable for strategic and operational oversight of the oncology research and development portfolio globally. Prior to Takeda/Millennium, Dr. Vasconcelles was group vice president and the Global Therapeutic Area Head, Transplant and Oncology, at Genzyme Corporation, where he was responsible for clinical development of the transplant and oncology portfolio and a member of the Transplant and Oncology Biness Unit Management Team. Following Sanofi's acquisition of Genzyme, Dr. Vasconcelles joined Sanofi Oncology as head, Personalized Medicine and Companion Diagnostics. From 1996 2021, Dr. Vasconcelles was a faculty member of the Harvard Medical School and an associate physician at Brigham and Women's Hospital and Dana Farber Cancer Institute. Dr. Vasconcelles has served on the board of directors of Kura Oncology, Inc. since September 2024. He received both his B.A. and M.D. from Northstern University.; Michael Vasconcelles，自2020年4月起担任Molecular Partners AG董事。他目前是Flatiron Health，Inc.的首席医疗官，在战略规划、思想领导和临床研究方法方面拥有专业知识。在2019年加入Flatiron Health之前，Vasconcelles博士在2015年至2019年期间担任联合国大学治疗学公司的首席医疗官。在联合国大学之前，他在武田/千禧大学工作了几年，负责研究和发展战略以及执行肿瘤学组合，从发现到产品许可和后期批准。Vasconcelles博士于1996年加入哈佛医学院，目前是哈佛医学院的临床医学讲师，也是Dana Farber癌症研究所和波士顿Brigham&Women医院的执业肿瘤学家和副医师。Vasconcelles博士是众多专业协会的成员，包括美国临床肿瘤学会和美国血液学学会。他的董事会承诺包括个性化医疗联盟和美国癌症协会的东新英格兰董事会。Vasconcelles博士完成了贝斯以色列医院内科学研究生培训和布里格姆女子医院血液肿瘤学研究，并从西北大学获得B.A。和M.D。; Michael Vasconcelles has served as a director since April 2020. He currently serves as head of research and development at Day One BioPharmaceuticals since June 2025. Previoly, he was executive vice president, Research, Development, and Medical Affairs at Immunogen from December 2022 until its acquisition by AbbVie in February 2024. Prior to Immunogen, he was chief medical officer and head of the Medical and Scientific Organization at Flatiron Health, a healthcare technology and services company foced on creating digital solutions to accelerate cancer research and improve patient care, from August 2019 to August 2022. Prior to joining Flatiron Health, Dr. Vasconcelles served as the chief medical officer of Unum Therapeutics Inc. (Unum) from October 2015 to July 2019, a Cambridge, MA based cell and gene therapy company. Prior to Unum, Dr. Vasconcelles spent several years at Takeda/Millennium, where he was senior vice president, Head of the Oncology Therapy Area Unit and member of the R&D Executive Team, accountable for strategic and operational oversight of the oncology research and development portfolio globally. Prior to Takeda/Millennium, Dr. Vasconcelles was group vice president and the Global Therapeutic Area Head, Transplant and Oncology, at Genzyme Corporation, where he was responsible for clinical development of the transplant and oncology portfolio and a member of the Transplant and Oncology Biness Unit Management Team. Following Sanofi's acquisition of Genzyme, Dr. Vasconcelles joined Sanofi Oncology as head, Personalized Medicine and Companion Diagnostics. From 1996 2021, Dr. Vasconcelles was a faculty member of the Harvard Medical School and an associate physician at Brigham and Women's Hospital and Dana Farber Cancer Institute. Dr. Vasconcelles has served on the board of directors of Kura Oncology, Inc. since September 2024. He received both his B.A. and M.D. from Northstern University.

Adam Dubow: Adam Dubow， 2013年至2015年-中国，日本，Intercon地区和EMAC地区副总裁兼法律总顾问。 2015年至2018年-研究与开发副总裁兼副总法律顾问。 2018年至今-高级副总裁，首席合规与道德官。

Adam Dubow has served as General Counsel since October 2022. Prior to joining Day One, Mr. Dubow held various leadership roles at Bristol Myers Squibb, a pharmaceutical company, from 1999 2021, including serving as the Senior Vice President and Chief Compliance and Ethics Officer from June 2018 to December 2021. From 2015 to 2018, Mr. Dubow served as Lead Counsel for the Global Research and Development organization at Bristol Myers Squibb. Prior to this role, he directed the Legal Teams for the Europe, Middle East & Africa, as well as the Asia Pacific and Japan Regions. From August, 1991 to September, 1999, Mr. Dubow was an Associate and then a Partner at Sedgwick LLP (f/k/a Sedgwick, Detert, Moran & Arnold LLP). Mr. Dubow received an undergraduate degree from Brandeis University and a J.D. from Fordham University School of Law.; Adam Dubow， 2013年至2015年-中国，日本，Intercon地区和EMAC地区副总裁兼法律总顾问。 2015年至2018年-研究与开发副总裁兼副总法律顾问。 2018年至今-高级副总裁，首席合规与道德官。; Adam Dubow has served as General Counsel since October 2022. Prior to joining Day One, Mr. Dubow held various leadership roles at Bristol Myers Squibb, a pharmaceutical company, from 1999 2021, including serving as the Senior Vice President and Chief Compliance and Ethics Officer from June 2018 to December 2021. From 2015 to 2018, Mr. Dubow served as Lead Counsel for the Global Research and Development organization at Bristol Myers Squibb. Prior to this role, he directed the Legal Teams for the Europe, Middle East & Africa, as well as the Asia Pacific and Japan Regions. From August, 1991 to September, 1999, Mr. Dubow was an Associate and then a Partner at Sedgwick LLP (f/k/a Sedgwick, Detert, Moran & Arnold LLP). Mr. Dubow received an undergraduate degree from Brandeis University and a J.D. from Fordham University School of Law.

Jeremy Bender: Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。

Jeremy Bender has served as Chief Executive Officer, President and a member of board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, Inc., a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics, Inc. from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, Inc., he was Vice President of Corporate Development at Allos Therapeutics Inc., a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma Group plc, a biotechnology company, since October 2020 as an independent board member. From October 2023 to June 2024, Dr. Bender also served as a director of Fusion Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.; Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。; Jeremy Bender has served as Chief Executive Officer, President and a member of board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, Inc., a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics, Inc. from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, Inc., he was Vice President of Corporate Development at Allos Therapeutics Inc., a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma Group plc, a biotechnology company, since October 2020 as an independent board member. From October 2023 to June 2024, Dr. Bender also served as a director of Fusion Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

Charles York II: Charles York II自2021年2月起担任公司首席运营官和首席财务官。加入Day One之前，他曾担任Aeglea生物制药公司公司（生物技术公司，专注于罕见代谢疾病）的首席财务官兼副总裁，在那里他曾领导投资者关系、企业发展、通信、财务规划、会计，2014年7月加入Aeglea担任财务副总裁后，自2015年9月起担任人力资源和信息技术。在加入Aeglea之前，York先生在生命科学，制药和技术行业担任财务管理职务，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）开始其职业生涯。York先生是亚利桑那州的注册会计师，并获得了康涅狄格大学的会计学学士学位和德克萨斯大学奥斯汀分校McCombs商学院的工商管理硕士学位。

Charles York II has over 20 years of experience in corporate finance in public and private enterprises in transactional and strategic capital formation roles, notably, operations, corporate and business development in the biotechnology industry. Previously, Mr. York served as Chief Financial Officer and Head of Corporate Development of Aeglea Biotherapeutics, Inc., a biotechnology company specializing in rare metabolic disease, where he led capital formation and allocation, investor relations, and corporate development from September 2015 to February 2021, after joining Aeglea as Vice President, Finance, in July 2014. Before Aeglea, Mr. York held financial management roles in the life science, pharmaceutical and technology industries and began his career at PricewaterhouseCoopers LLP. Mr. York is a CPA in the state of Arizona (inactive) and received a B.S. in Accounting from the University of Connecticut and an M.B.A. from the McCombs School of Business at the University of Texas at Austin.; Charles York II自2021年2月起担任公司首席运营官和首席财务官。加入Day One之前，他曾担任Aeglea生物制药公司公司（生物技术公司，专注于罕见代谢疾病）的首席财务官兼副总裁，在那里他曾领导投资者关系、企业发展、通信、财务规划、会计，2014年7月加入Aeglea担任财务副总裁后，自2015年9月起担任人力资源和信息技术。在加入Aeglea之前，York先生在生命科学，制药和技术行业担任财务管理职务，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）开始其职业生涯。York先生是亚利桑那州的注册会计师，并获得了康涅狄格大学的会计学学士学位和德克萨斯大学奥斯汀分校McCombs商学院的工商管理硕士学位。; Charles York II has over 20 years of experience in corporate finance in public and private enterprises in transactional and strategic capital formation roles, notably, operations, corporate and business development in the biotechnology industry. Previously, Mr. York served as Chief Financial Officer and Head of Corporate Development of Aeglea Biotherapeutics, Inc., a biotechnology company specializing in rare metabolic disease, where he led capital formation and allocation, investor relations, and corporate development from September 2015 to February 2021, after joining Aeglea as Vice President, Finance, in July 2014. Before Aeglea, Mr. York held financial management roles in the life science, pharmaceutical and technology industries and began his career at PricewaterhouseCoopers LLP. Mr. York is a CPA in the state of Arizona (inactive) and received a B.S. in Accounting from the University of Connecticut and an M.B.A. from the McCombs School of Business at the University of Texas at Austin.

Lauren Merendino: Lauren Merendino自2021年4月起担任Myovant SciencesLtd.和Myovant Sciences，Inc.的首席商务官。从2018年9月到2021年4月，Merendino女士担任Genentech，Inc.（制药公司）神经罕见疾病副总裁，在那里，她负责领导一个跨职能团队，以推出神经系统罕见疾病治疗领域的产品，并领导销售、营销、市场准入、医疗事务和政府事务及宣传方面的合作努力。从2009年9月到2018年9月，梅伦迪诺女士还在Genentech担任多个其他职位，在那里她在销售、营销、定价、市场准入和客户洞察力的商业组织中承担越来越多的责任，专注于神经科学和肿瘤领域。在加入Genentech之前，从1997年8月到2009年8月，梅伦迪诺女士在罗氏制药公司（Roche）担任过多个职位，她在该公司负责乳腺癌和结直肠癌领域的药品营销，主要负责战术规划和促销产品的执行、患者支持计划，医疗团队互动，销售团队界面，销售培训，顾问委员会和市场调研。在Roche and Genentech任职期间，她在国家销售、市场营销以及早期开发和商业开发交易中的分子商业策略方面拥有广泛的经验。她在宾夕法尼亚州立大学获得了微生物学学士学位，在纽约大学获得了营销和管理硕士学位。

Lauren Merendino has served as Chief Commercial Officer since June 2023. Prior to joining Day One, Ms. Merendino served as Chief Commercial Officer at Myovant Sciences Ltd., a biotechnology company, from April 2021 to April 2023. Prior to that, Ms. Merendino served in various roles at Genentech Inc., a biopharmaceutical company, from September 2009 to April 2021, including Vice President of Neurological Rare Diseases and Senior Director of Pipeline – Neuroscience, Rare Disease, Pediatrics and Anti infectives. From June 2023 to March 2025, Ms. Merendino served as the lead independent director at ESSA Pharma Inc., a biopharmaceutical company. Ms. Merendino received a B.S. in Microbiology from Penn State University and completed her M.B.A. at New York University.; Lauren Merendino自2021年4月起担任Myovant SciencesLtd.和Myovant Sciences，Inc.的首席商务官。从2018年9月到2021年4月，Merendino女士担任Genentech，Inc.（制药公司）神经罕见疾病副总裁，在那里，她负责领导一个跨职能团队，以推出神经系统罕见疾病治疗领域的产品，并领导销售、营销、市场准入、医疗事务和政府事务及宣传方面的合作努力。从2009年9月到2018年9月，梅伦迪诺女士还在Genentech担任多个其他职位，在那里她在销售、营销、定价、市场准入和客户洞察力的商业组织中承担越来越多的责任，专注于神经科学和肿瘤领域。在加入Genentech之前，从1997年8月到2009年8月，梅伦迪诺女士在罗氏制药公司（Roche）担任过多个职位，她在该公司负责乳腺癌和结直肠癌领域的药品营销，主要负责战术规划和促销产品的执行、患者支持计划，医疗团队互动，销售团队界面，销售培训，顾问委员会和市场调研。在Roche and Genentech任职期间，她在国家销售、市场营销以及早期开发和商业开发交易中的分子商业策略方面拥有广泛的经验。她在宾夕法尼亚州立大学获得了微生物学学士学位，在纽约大学获得了营销和管理硕士学位。; Lauren Merendino has served as Chief Commercial Officer since June 2023. Prior to joining Day One, Ms. Merendino served as Chief Commercial Officer at Myovant Sciences Ltd., a biotechnology company, from April 2021 to April 2023. Prior to that, Ms. Merendino served in various roles at Genentech Inc., a biopharmaceutical company, from September 2009 to April 2021, including Vice President of Neurological Rare Diseases and Senior Director of Pipeline – Neuroscience, Rare Disease, Pediatrics and Anti infectives. From June 2023 to March 2025, Ms. Merendino served as the lead independent director at ESSA Pharma Inc., a biopharmaceutical company. Ms. Merendino received a B.S. in Microbiology from Penn State University and completed her M.B.A. at New York University.

Lauren Merendino: Lauren Merendino自2023年6月起担任首席商务官。在加入Day One之前，Merendino女士于2021年4月至2023年4月在生物技术公司Myovant Sciences Ltd.担任首席商务官。在此之前，Merendino女士曾于2009年9月至2021年4月在生物制药公司Genentech Inc.担任多个职务，包括神经学罕见疾病副总裁和管道-神经科学、罕见病、儿科和抗感染药物高级总监。2023年6月至2025年3月，Merendino女士在生物制药公司ESSA制药公司担任首席独立董事。Merendino女士获得了宾夕法尼亚州立大学微生物学学士学位，并在纽约大学完成了工商管理硕士学位。

Lauren Merendino has served as Chief Commercial Officer since June 2023. Prior to joining Day One, Ms. Merendino served as Chief Commercial Officer at Myovant Sciences Ltd., a biotechnology company, from April 2021 to April 2023. Prior to that, Ms. Merendino served in various roles at Genentech Inc., a biopharmaceutical company, from September 2009 to April 2021, including Vice President of Neurological Rare Diseases and Senior Director f Pipeline – Neuroscience, Rare Disease, Pediatrics and Anti infectives. From June 2023 to March 2025, Ms. Merendino served as the lead independent director at ESSA Pharma Inc., a biopharmaceutical company. Ms. Merendino received a B.S. in Microbiology from Penn State University and completed her M.B.A. at New York University.; Lauren Merendino自2023年6月起担任首席商务官。在加入Day One之前，Merendino女士于2021年4月至2023年4月在生物技术公司Myovant Sciences Ltd.担任首席商务官。在此之前，Merendino女士曾于2009年9月至2021年4月在生物制药公司Genentech Inc.担任多个职务，包括神经学罕见疾病副总裁和管道-神经科学、罕见病、儿科和抗感染药物高级总监。2023年6月至2025年3月，Merendino女士在生物制药公司ESSA制药公司担任首席独立董事。Merendino女士获得了宾夕法尼亚州立大学微生物学学士学位，并在纽约大学完成了工商管理硕士学位。; Lauren Merendino has served as Chief Commercial Officer since June 2023. Prior to joining Day One, Ms. Merendino served as Chief Commercial Officer at Myovant Sciences Ltd., a biotechnology company, from April 2021 to April 2023. Prior to that, Ms. Merendino served in various roles at Genentech Inc., a biopharmaceutical company, from September 2009 to April 2021, including Vice President of Neurological Rare Diseases and Senior Director f Pipeline – Neuroscience, Rare Disease, Pediatrics and Anti infectives. From June 2023 to March 2025, Ms. Merendino served as the lead independent director at ESSA Pharma Inc., a biopharmaceutical company. Ms. Merendino received a B.S. in Microbiology from Penn State University and completed her M.B.A. at New York University.

Michael Vasconcelles: Michael Vasconcelles自2025年6月起担任Day One Biopharmaceuticals, Inc.研发主管。在加入Day One之前，Vasconcelles博士于2022年12月至2024年2月期间在ImmunoGen公司（现为艾伯维的一部分）担任执行副总裁兼研究、开发和医疗事务主管。在此之前，他曾于2019年8月至2022年8月担任罗氏集团全资子公司Flatiron Health的首席医疗官兼医学和科学组织负责人。2015年10月至2019年7月，他担任Unum Therapeutics Inc.的首席医疗官，该公司是一家上市生物技术公司，现名为Cogent Biosciences, Inc.。2012年至2015年，Vasconcelles博士担任Millenium、Takeda Pharmaceutical Company Limited和Takeda Pharmaceuticals International Co.的全资子公司Takeda Oncology Company的高级副总裁兼肿瘤治疗领域单位的全球负责人。2000年至2011年，Vasconcelles博士在健赞担任越来越重要的职务，包括集团副总裁以及移植和肿瘤学的全球治疗领域负责人。继Genzyme在2011年被赛诺菲收购后，Vasconcelles博士在赛诺菲担任个性化医学和伴随诊断负责人，直到2012年。Vasconcelles博士自2024年9月起担任Kura Oncology，Inc.的董事会成员，自2020年4月起担任Molecular Partners AG的董事会成员，自2019年起担任东部新英格兰美国癌症协会（至2025年）的董事会成员，自2012年起担任个性化医疗联盟的董事会成员。Vasconcelles博士获得了西北大学的学士和医学博士学位。

Michael Vasconcelles has served as Day One Biopharmaceuticals, Inc.'s Head of Research and Development since June 2025. Prior to joining Day One, Dr. Vasconcelles served as Executive Vice President and Head of Research, Development and Medical Affairs at ImmunoGen, Inc., now part of AbbVie, from December 2022 to February 2024. Prior to that, he served as the Chief Medical Officer and Head of the Medical and Scientific Organization of Flatiron Health, a wholly owned subsidiary of the Roche Group, from August 2019 to August 2022. From October 2015 to July 2019, he served as Chief Medical Officer of Unum Therapeutics Inc., a public biotechnology company now known as Cogent Biosciences, Inc. From 2012 to 2015, Dr. Vasconcelles was Senior Vice President and Global Head of the Oncology Therapy Area Unit at Millenium, The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals International Co. From 2000 to 2011, Dr. Vasconcelles held positions of increasing responsibility at Genzyme Corporation, including Group Vice President and the Global Therapeutic Area Head of Transplant and Oncology. Following Genzyme's acquisition by Sanofi in 2011, Dr. Vasconcelles served as Head of Personalized Medicine and Companion Diagnostics at Sanofi until 2012. Dr. Vasconcelles has served on the board of directors of Kura Oncology, Inc. since September 2024, Molecular Partners AG since April 2020, the Eastern New England American Cancer Society since 2019 (through 2025) and the Personalized Medicine Coalition since 2012. Dr. Vasconcelles earned his B.A. and M.D. from Northwestern University.; Michael Vasconcelles自2025年6月起担任Day One Biopharmaceuticals, Inc.研发主管。在加入Day One之前，Vasconcelles博士于2022年12月至2024年2月期间在ImmunoGen公司（现为艾伯维的一部分）担任执行副总裁兼研究、开发和医疗事务主管。在此之前，他曾于2019年8月至2022年8月担任罗氏集团全资子公司Flatiron Health的首席医疗官兼医学和科学组织负责人。2015年10月至2019年7月，他担任Unum Therapeutics Inc.的首席医疗官，该公司是一家上市生物技术公司，现名为Cogent Biosciences, Inc.。2012年至2015年，Vasconcelles博士担任Millenium、Takeda Pharmaceutical Company Limited和Takeda Pharmaceuticals International Co.的全资子公司Takeda Oncology Company的高级副总裁兼肿瘤治疗领域单位的全球负责人。2000年至2011年，Vasconcelles博士在健赞担任越来越重要的职务，包括集团副总裁以及移植和肿瘤学的全球治疗领域负责人。继Genzyme在2011年被赛诺菲收购后，Vasconcelles博士在赛诺菲担任个性化医学和伴随诊断负责人，直到2012年。Vasconcelles博士自2024年9月起担任Kura Oncology，Inc.的董事会成员，自2020年4月起担任Molecular Partners AG的董事会成员，自2019年起担任东部新英格兰美国癌症协会（至2025年）的董事会成员，自2012年起担任个性化医疗联盟的董事会成员。Vasconcelles博士获得了西北大学的学士和医学博士学位。; Michael Vasconcelles has served as Day One Biopharmaceuticals, Inc.'s Head of Research and Development since June 2025. Prior to joining Day One, Dr. Vasconcelles served as Executive Vice President and Head of Research, Development and Medical Affairs at ImmunoGen, Inc., now part of AbbVie, from December 2022 to February 2024. Prior to that, he served as the Chief Medical Officer and Head of the Medical and Scientific Organization of Flatiron Health, a wholly owned subsidiary of the Roche Group, from August 2019 to August 2022. From October 2015 to July 2019, he served as Chief Medical Officer of Unum Therapeutics Inc., a public biotechnology company now known as Cogent Biosciences, Inc. From 2012 to 2015, Dr. Vasconcelles was Senior Vice President and Global Head of the Oncology Therapy Area Unit at Millenium, The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals International Co. From 2000 to 2011, Dr. Vasconcelles held positions of increasing responsibility at Genzyme Corporation, including Group Vice President and the Global Therapeutic Area Head of Transplant and Oncology. Following Genzyme's acquisition by Sanofi in 2011, Dr. Vasconcelles served as Head of Personalized Medicine and Companion Diagnostics at Sanofi until 2012. Dr. Vasconcelles has served on the board of directors of Kura Oncology, Inc. since September 2024, Molecular Partners AG since April 2020, the Eastern New England American Cancer Society since 2019 (through 2025) and the Personalized Medicine Coalition since 2012. Dr. Vasconcelles earned his B.A. and M.D. from Northwestern University.

Adam Dubow: Adam Dubow自2022年10月起担任总法律顾问。在加入Day One之前，Dubow先生于1999年至2021年在制药公司百时美施贵宝担任过各种领导职务，包括于2018年6月至2021年12月担任高级副总裁兼首席合规和道德官。从2015年到2018年，Dubow先生担任百时美施贵宝全球研发组织的首席法律顾问。在担任这一职务之前，他曾指导欧洲、中东和非洲以及亚太地区和日本地区的法律团队。从1991年8月至1999年9月，Dubow先生是Sedgwick LLP（f/k/a Sedgwick，Detert，Moran & Arnold LLP）的合伙人和合伙人。Dubow先生获得了布兰代斯大学的本科学位和福特汉姆大学法学院的法学博士学位。

Adam Dubow has served as General Counsel since October 2022. Prior to joining Day One, Mr. Dubow held various leadership roles at Bristol Myers Squibb, a pharmaceutical company, from 1999 2021, including serving as the Senior Vice President and Chief Compliance and Ethics Officer from June 2018 to December 2021. From 2015 to 2018, Mr. Dubow served as Lead Counsel for the Global Research and Development organization at Bristol Myers Squibb. Prior to this role, he directed the Legal Teams for the Europe, Middle East & Africa, as well as the Asia Pacific and Japan Regions. From August, 1991 to September, 1999, Mr. Dubow was an Associate and then a Partner at Sedgwick LLP (f/k/a Sedgwick, Detert, Moran & Arnold LLP). Mr. Dubow received an undergraduate degree from Brandeis University and a J.D. from Fordham University School of Law.; Adam Dubow自2022年10月起担任总法律顾问。在加入Day One之前，Dubow先生于1999年至2021年在制药公司百时美施贵宝担任过各种领导职务，包括于2018年6月至2021年12月担任高级副总裁兼首席合规和道德官。从2015年到2018年，Dubow先生担任百时美施贵宝全球研发组织的首席法律顾问。在担任这一职务之前，他曾指导欧洲、中东和非洲以及亚太地区和日本地区的法律团队。从1991年8月至1999年9月，Dubow先生是Sedgwick LLP（f/k/a Sedgwick，Detert，Moran & Arnold LLP）的合伙人和合伙人。Dubow先生获得了布兰代斯大学的本科学位和福特汉姆大学法学院的法学博士学位。; Adam Dubow has served as General Counsel since October 2022. Prior to joining Day One, Mr. Dubow held various leadership roles at Bristol Myers Squibb, a pharmaceutical company, from 1999 2021, including serving as the Senior Vice President and Chief Compliance and Ethics Officer from June 2018 to December 2021. From 2015 to 2018, Mr. Dubow served as Lead Counsel for the Global Research and Development organization at Bristol Myers Squibb. Prior to this role, he directed the Legal Teams for the Europe, Middle East & Africa, as well as the Asia Pacific and Japan Regions. From August, 1991 to September, 1999, Mr. Dubow was an Associate and then a Partner at Sedgwick LLP (f/k/a Sedgwick, Detert, Moran & Arnold LLP). Mr. Dubow received an undergraduate degree from Brandeis University and a J.D. from Fordham University School of Law.

Day OneDAWN

董事介绍

高管介绍

董事简历

高管简历

Day One
DAWN